Expression of integrin-binding protein Nischarin in metastatic breast cancer

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 77-82

  Chen, Jie ^a   Feng, Wei Liang ^a   Mo, Wen Ju ^a   Ding, Xiao Wen ^a   Xie, Shang Nao ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Breast cancer; Metastasis; Nischarin

Indexed keywords

BINDING PROTEIN; NISCHARIN PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; IMIDAZOLINE RECEPTOR; MESSENGER RNA; NISCH PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER GRADING; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLINE RECEPTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER;

EID: 84926655034     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3373     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
3. Perez EA, Romond EH, Suman VJ, et al: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744-3752, 2014.
4. Albain KS, Barlow WE, Ravdin PM, et al; Breast Cancer Intergroup of North America: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374: 2055-2063.
5. Clarke M, Collins R, Darby S, et al; Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087-2106, 2005.
6. Aebi S, Davidson T, Gruber G and Cardoso F; ESMO Guidelines Working Group: Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22 (Suppl 6): vi12-vi24, 2011.
7. Tazhibi M, Fayaz M and Mokarian F: Detection of prognostic factors in metastatic breast cancer. J Res Med Sci 18: 283-290, 2013.
8. Cadoo KA, Fornier MN and Morris PG: Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging 57: 312-321, 2013.
9. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 351: 781-791, 2004.
10. Whale A, Hashim FN, Fram S, Jones GE and Wells CM: Signalling to cancer cell invasion through PAK family kinases. Front Biosci (Landmark Ed) 16: 849-864, 2011.
11. Redig AJ and McAllister SS: Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274: 113-126, 2013.
12. Kjoller L and Hall A: Signaling to Rho GTPases. Exp Cell Res 253: 166-179, 1999.
13. Bagrodia S and Cerione RA: Pak to the future. Trends Cell Biol 9: 350-355, 1999.
14. Szczepanowska J: Involvement of Rac/Cdc42/PAK pathway in cytoskeletal rearrangements. Acta Biochim Pol 56: 225-234, 2009.
15. Edwards DC, Sanders LC, Bokoch GM and Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1: 253-259, 1999.
16. Martinez A, Walker RA, Shaw JA, Dearing SJ, Maher ER and Latif F: Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 54: 300-306, 2001.
17. Killary AM, Wolf ME, Giambernardi TA and Naylor SL: Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 89: 10877-10881,1992.
18. Ma H, Li W and Wu N: Advances in new Nischarin protein. Chinese Pharmacological Bulletin 26: 4, 2010 (In Chinese).
19. Alahari SK, Lee JW and Juliano RL: Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol 151: 1141-1154, 2000.
20. Alahari SK: Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp Cell Res 288: 415-424, 2003.
21. Alahari SK and Nasrallah H: A membrane proximal region of the integrin alpha5 subunit is important for its interaction with nischarin. Biochem J 377: 449-457, 2004.
22. Ivanov TR, Jones JC, Dontenwill M, Bousquet P and Piletz JE: Characterization of a partial cDNA clone detected by imidazoline receptor-selective antisera. J Auton Nerv Syst 72: 98-110, 1998.
23. Dontenwill M, Pascal G, Piletz JE, et al: IRAS, the human homologue of Nischarin, prolongs survival of transfected PC12 cells. Cell Death Differ 10: 933-935, 2003.
24. Dontenwill M, Piletz JE, Chen M, et al: IRAS is an anti-apoptotic protein. Ann N Y Acad Sci 1009: 400-412, 2003.
25. Ding Y, Zhang R, Zhang K, et al: Nischarin is differentially expressed in rat brain and regulates neuronal migration. PLoS One 8: e54563, 2013.
26. Baranwal S, Wang Y, Rathinam R, et al: Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst 103: 1513-1528, 2011.
27. Jain P, Baranwal S, Dong S, Struckhoff AP, Worthylake RA and Alahari SK: Integrin-binding protein nischarin interacts with tumor suppressor liver kinase B1 (LKB1) to regulate cell migration of breast epithelial cells. J Biol Chem 288: 15495-15509, 2013.
28. Edge S, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, 2010.
29. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20: 3628-3636, 2002.
30. Harris L, Fritsche H, Mennel R, et al; American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312, 2007.
31. Assoian RK: Anchorage-dependent cell cycle progression. J Cell Biol 136: 1-4, 1997.
32. Frisch SM and Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol 9: 701-706, 1997.
33. Varner JA, Emerson DA and Juliano RL: Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 6: 725-740, 1995.
34. Zhang Z, Vuori K, Reed JC and Ruoslahti E: The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92: 6161-6165, 1995.
35. Hu JJ, Lei H T, Hou and YM: A new evaluation method for tumor cell migration process. Chinese Pharmacological Bulletin 1: 128-131, 2010.
36. Alahari SK, Reddig PJ and Juliano RL: The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK. EMBO J 23: 2777-2788, 2004.
37. Reddig PJ, Xu D and Juliano RL: Regulation of p21-activated kinase-independent Rac1 signal transduction by nischarin. J Biol Chem 280: 30994-31002, 2005.
38. Davila M, Frost AR, Grizzle WE and Chakrabarti R: LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem 278: 36868-36875, 2003.
39. Yoshioka K, Foletta V, Bernard O and Itoh K: A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 100: 7247-7252, 2003.
40. Bagheri-Yarmand R, Mazumdar A, Sahin AA and Kumar R: LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 118: 2703-2710, 2006.
41. Nishita M, Tomizawa C, Yamamoto M, Horita Y, Ohashi K and Mizuno K: Spatial and temporal regulation of cofilin activity by LIM kinase and Slingshot is critical for directional cell migration. J Cell Biol 171: 349-359, 2005.
42. Soosairajah J, Maiti S, Wiggan O, et al: Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin. EMBO J 24: 473-486, 2005.
43. Ding Y, Milosavljevic T and Alahari SK: Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion. Mol Cell Biol 28: 3742-3756, 2008.
44. Jackson RJ and Standart N: How do microRNAs regulate gene expression? Sci STKE 2007: re1, 2007.
45. Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF and TNF-α in breast cancer. Cancer Res 73: 2884-2896, 2013.